Proving to be safe and immunogenic in a phase I trial of breast cancer patients [76], a primary report published by Mittendorf et al. in 2012 on a phase II, randomized controlled trial of the AE37 vaccine in the adjuvant setting in disease-free patients with node-positive and high-risk node-negative breast cancer to prevent disease recurrence (NCT00524277) provided promising evidence of efficacy of the vaccine in HER2-low expressing breast cancer subtypes, including TNBC patients. Here, ERBB2 is linked to breast carcinoma.